<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cision Wire</title>
    <link>http://www.cisionwire.com</link>
    <description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description>
    <pubDate>Fri, 10 Feb 2012 07:18:15 GMT</pubDate>
    <image>
      <title>Cision Wire</title>
      <width>120</width>
      <height>32</height>
      <link>http://www.cisionwire.com</link>
      <url>http://www.cisionwire.com/images/CisionLogoSmall.gif</url>
    </image>
    <item>
      <title>REPURCHASE OF SHARES IN ASTRAZENECA PLC</title>
      <link>http://www.cisionwire.com/astrazeneca/r/repurchase-of-shares-in-astrazeneca-plc,c9218336</link>
      <guid isPermaLink="false">cision450017</guid>
      <description><![CDATA[<p><strong></strong>&nbsp;</p>]]></description>
      <pubDate>Thu, 09 Feb 2012 09:20:25 GMT</pubDate>
    </item>
    <item>
      <title>MOBERG DERMA YEAR–END REPORT 2011</title>
      <link>http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-year-end-report-2011,c9217842</link>
      <guid isPermaLink="false">cision449806</guid>
      <description><![CDATA[<p><strong>STRONG REVENUE GROWTH AND SIGNIFICANTLY IMPROVED EARNINGS</strong></p>]]></description>
      <pubDate>Thu, 09 Feb 2012 07:00:00 GMT</pubDate>
    </item>
    <item>
      <title>FURTHER STUDIES MAY BE REQUIRED FOR MOB-015</title>
      <link>http://www.cisionwire.com/moberg-derma-ab/r/further-studies-may-be-required-for-mob-015,c9218148</link>
      <guid isPermaLink="false">cision449778</guid>
      <description><![CDATA[<p></p>
<p><strong>Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be completed and results are expected by the end of the year.</strong></p>
<p></p>]]></description>
      <pubDate>Thu, 09 Feb 2012 06:59:00 GMT</pubDate>
    </item>
    <item>
      <title>DiaGenic reports high 85% accuracy for blood based diagnosis in early Parkinson patients in European multicenter study</title>
      <link>http://www.cisionwire.com/diagenic-asa/r/diagenic-reports-high-85--accuracy-for-blood-based-diagnosis-in-early-parkinson-patients-in-european,c9217974</link>
      <guid isPermaLink="false">cision449640</guid>
      <description><![CDATA[<p><strong></strong>&nbsp;</p>]]></description>
      <pubDate>Wed, 08 Feb 2012 16:28:05 GMT</pubDate>
    </item>
    <item>
      <title>REPURCHASE OF SHARES IN ASTRAZENECA PLC</title>
      <link>http://www.cisionwire.com/astrazeneca/r/repurchase-of-shares-in-astrazeneca-plc,c9217628</link>
      <guid isPermaLink="false">cision449257</guid>
      <description><![CDATA[<p><strong></strong>&nbsp;</p>]]></description>
      <pubDate>Wed, 08 Feb 2012 09:14:57 GMT</pubDate>
    </item>
    <item>
      <title>INTERIM REPORT JANUARY - DECEMBER 2011</title>
      <link>http://www.cisionwire.com/karo-bio/r/interim-report-january---december-2011,c9217516</link>
      <guid isPermaLink="false">cision449150</guid>
      <description><![CDATA[<p><strong></strong></p>]]></description>
      <pubDate>Wed, 08 Feb 2012 07:30:00 GMT</pubDate>
    </item>
    <item>
      <title>REPURCHASE OF SHARES IN ASTRAZENECA PLC</title>
      <link>http://www.cisionwire.com/astrazeneca/r/repurchase-of-shares-in-astrazeneca-plc,c9217081</link>
      <guid isPermaLink="false">cision448692</guid>
      <description><![CDATA[<p><strong></strong>&nbsp;</p>]]></description>
      <pubDate>Tue, 07 Feb 2012 11:26:08 GMT</pubDate>
    </item>
    <item>
      <title>Presentation of results for fourth quarter 2011</title>
      <link>http://www.cisionwire.com/diagenic-asa/r/presentation-of-results-for-fourth-quarter-2011,c9216980</link>
      <guid isPermaLink="false">cision448556</guid>
      <description><![CDATA[<p><strong></strong></p>]]></description>
      <pubDate>Tue, 07 Feb 2012 09:11:46 GMT</pubDate>
    </item>
    <item>
      <title>REPURCHASE OF SHARES IN ASTRAZENECA PLC</title>
      <link>http://www.cisionwire.com/astrazeneca/r/repurchase-of-shares-in-astrazeneca-plc,c9216784</link>
      <guid isPermaLink="false">cision448343</guid>
      <description><![CDATA[<p><strong></strong>&nbsp;</p>]]></description>
      <pubDate>Mon, 06 Feb 2012 16:07:19 GMT</pubDate>
    </item>
    <item>
      <title>ASTRAZENECA PLC IRREVOCABLE, NON-DISCRETIONARY SHARE REPURCHASE PROGRAMME</title>
      <link>http://www.cisionwire.com/astrazeneca/r/astrazeneca-plc-irrevocable--non-discretionary-share-repurchase-programme,c9215510</link>
      <guid isPermaLink="false">cision447138</guid>
      <description><![CDATA[<p></p>
<p>REPURCHASE OF SHARES IN ASTRAZENECA PLC 2nd AND 3rd FEBRUARY</p>
<p></p>]]></description>
      <pubDate>Fri, 03 Feb 2012 15:25:16 GMT</pubDate>
    </item>
  </channel>
</rss>
